Mehlman Consulting, Inc.
Mehlman Consulting, Inc. filed a Q1 report for The Campaign for Sustainable RX Pricing on April 17, 2025, reporting $90,000 in lobbying income.
Lobbying for The Campaign for Sustainable RX Pricing · A coalition of organizations working on market-based solutions to drug pricing.
Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act.
Prescription drug pricing issues. H.R. 1843/S. 1302 - Increasing Transparency in Generic Drug Applications Act.
Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act.